Prokarium

Executive Summary

Prokarium is a clinical-stage biopharmaceutical company developing microbial immunotherapies based on a proprietary engineered strain of Salmonella, ZH9. The platform is designed to selectively target tumors, disrupt the immunosuppressive tumor microenvironment, and stimulate systemic anti-tumor immunity. Prokarium's lead program is in Phase 1 clinical trials for bladder cancer, with the potential to expand into other solid tumors. The company was founded in 2012 and is headquartered in London, UK. The company's approach represents a novel modality in immuno-oncology, leveraging bacteria as a living therapeutic to deliver diverse payloads directly to tumors. While still early-stage, Prokarium has the opportunity to address significant unmet needs in cancers resistant to conventional checkpoint inhibitors. Key risks include the inherent challenge of bacterial therapy safety, manufacturing complexity, and the need for substantial funding to advance through later-stage trials. Success hinges on positive Phase 1 data that demonstrates safety and preliminary efficacy, which could attract partnership interest and further investment.

Upcoming Catalysts (preview)

• TBDPhase 1 Bladder Cancer Trial Data Readout60% success
• TBDStrategic Partnership or Licensing Deal for ZH9 Platform40% success
• TBDSeries B or C Financing Round70% success